

Small Misfolded Tau Species Are Internalized via Bulk Endocytosis and Retrogradely Transported in Neurons

Journal of Biological Chemistry

288, 1856-1870

DOI: [10.1074/jbc.m112.394528](https://doi.org/10.1074/jbc.m112.394528)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Prion-Like Propagation of Protein Aggregation and Related Therapeutic Strategies. <i>Neurotherapeutics</i> , 2013, 10, 371-382.	2.1	33
2	Untangling the role of tau in Alzheimer's disease: A unifying hypothesis. <i>Translational Neuroscience</i> , 2013, 4, 115-133.	0.7	9
3	Transfer of polyglutamine aggregates in neuronal cells occurs in tunneling nanotubes. <i>Journal of Cell Science</i> , 2013, 126, 3678-85.	1.2	157
4	Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. <i>Nature</i> , 2013, 501, 45-51.	13.7	1,331
5	Amyotrophic lateral sclerosis—a model of corticofugal axonal spread. <i>Nature Reviews Neurology</i> , 2013, 9, 708-714.	4.9	432
6	The cell biology of prion-like spread of protein aggregates: mechanisms and implication in neurodegeneration. <i>Biochemical Journal</i> , 2013, 452, 1-17.	1.7	126
7	Endogenous Tau Aggregates in Oligodendrocytes of rTg4510 Mice Induced by Human P301L Tau. <i>Journal of Alzheimer's Disease</i> , 2013, 38, 589-600.	1.2	11
8	TOC1: Characterization of a Selective Oligomeric Tau Antibody. <i>Journal of Alzheimer's Disease</i> , 2013, 37, 593-602.	1.2	50
9	Neurodegenerative lesions: Seeding and spreading. <i>Revue Neurologique</i> , 2013, 169, 825-833.	0.6	24
11	Tau pathology and neurodegeneration. <i>Lancet Neurology</i> , The, 2013, 12, 609-622.	4.9	893
12	Prion-Like Templated Misfolding in Tauopathies. <i>Brain Pathology</i> , 2013, 23, 342-349.	2.1	114
13	Calcium Entry and Synuclein Inclusions Elevate Dendritic Mitochondrial Oxidant Stress in Dopaminergic Neurons. <i>Journal of Neuroscience</i> , 2013, 33, 10154-10164.	1.7	174
14	Mechanistic Studies Unravel the Complexity Inherent in Tau Aggregation Leading to Alzheimer's Disease and the Tauopathies. <i>Biochemistry</i> , 2013, 52, 4107-4126.	1.2	51
15	Trimeric Tau Is Toxic to Human Neuronal Cells at Low Nanomolar Concentrations. <i>International Journal of Cell Biology</i> , 2013, 2013, 1-9.	1.0	70
16	Rapid Accumulation of Endogenous Tau Oligomers in a Rat Model of Traumatic Brain Injury. <i>Journal of Biological Chemistry</i> , 2013, 288, 17042-17050.	1.6	115
17	Prions <i>Ex Vivo</i> : What Cell Culture Models Tell Us about Infectious Proteins. <i>International Journal of Cell Biology</i> , 2013, 2013, 1-14.	1.0	16
18	The Involvement of Cholinergic Neurons in the Spreading of Tau Pathology. <i>Frontiers in Neurology</i> , 2013, 4, 74.	1.1	20
19	Tangles, Toxicity, and Tau Secretion in AD — New Approaches to a Vexing Problem. <i>Frontiers in Neurology</i> , 2013, 4, 160.	1.1	49

#	ARTICLE	IF	CITATIONS
20	Spreading of tau pathology in Alzheimer's disease by cell-to-cell transmission. <i>European Journal of Neuroscience</i> , 2013, 37, 1939-1948.	1.2	106
21	Life cycle of cytosolic prions. <i>Prion</i> , 2013, 7, 369-377.	0.9	11
22	Propagation of tau pathology in Alzheimer's disease: identification of novel therapeutic targets. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 49.	3.0	84
23	Formation and Propagation of Tau Oligomeric Seeds. <i>Frontiers in Neurology</i> , 2013, 4, 93.	1.1	95
24	The Importance of Tau Phosphorylation for Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , 2013, 4, 83.	1.1	312
25	Evidence for Prion-Like Mechanisms in Several Neurodegenerative Diseases: Potential Implications for Immunotherapy. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-20.	3.3	30
26	Rescue of tau-induced synaptic transmission pathology by paclitaxel. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 34.	1.8	18
27	The role of extracellular Tau in the spreading of neurofibrillary pathology. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 113.	1.8	130
28	Prions and Prion-Like Pathogens in Neurodegenerative Disorders. <i>Pathogens</i> , 2014, 3, 149-163.	1.2	14
29	Frequent and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic terminals in Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2014, 2, 146.	2.4	79
30	Extracellular Monomeric Tau Protein Is Sufficient to Initiate the Spread of Tau Protein Pathology. <i>Journal of Biological Chemistry</i> , 2014, 289, 956-967.	1.6	153
31	Stages and Conformations of the Tau Repeat Domain during Aggregation and Its Effect on Neuronal Toxicity. <i>Journal of Biological Chemistry</i> , 2014, 289, 20318-20332.	1.6	77
32	Axonal tract tracing for delineating interacting brain regions: implications for Alzheimer's disease-associated memory. <i>Future Neurology</i> , 2014, 9, 89-98.	0.9	3
33	Specific Targeting of Tau Oligomers in Htau Mice Prevents Cognitive Impairment and Tau Toxicity Following Injection with Brain-Derived Tau Oligomeric Seeds. <i>Journal of Alzheimer's Disease</i> , 2014, 40, S97-S111.	1.2	145
34	Could Intracrine Biology Play a Role in the Pathogenesis of Transmissible Spongiform Encephalopathies Alzheimer's Disease and Other Neurodegenerative Diseases?. <i>American Journal of the Medical Sciences</i> , 2014, 347, 312-320.	0.4	9
35	<i>Nos2</i> Deletion and Human <i>NOS2</i> Replacement in Alzheimer Disease Models. <i>Journal of Neuropathology and Experimental Neurology</i> , 2014, 73, 752-769.	0.9	30
36	Neuron-to-neuron wild-type Tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies. <i>Acta Neuropathologica Communications</i> , 2014, 2, 14.	2.4	203
37	A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. <i>Acta Neuropathologica</i> , 2014, 127, 667-683.	3.9	390

#	ARTICLE	IF	CITATIONS
38	Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles. <i>Journal of Neuroscience</i> , 2014, 34, 4260-4272.	1.7	241
39	Intracellular and Extracellular Roles for Tau in Neurodegenerative Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 40, S37-S45.	1.2	45
40	Systems Approach to Neurodegenerative Disease Biomarker Discovery. <i>Annual Review of Pharmacology and Toxicology</i> , 2014, 54, 457-481.	4.2	45
41	Alzheimer disease therapeutics: Focus on the disease and not just plaques and tangles. <i>Biochemical Pharmacology</i> , 2014, 88, 631-639.	2.0	95
42	Emerging Therapeutics for Alzheimer's Disease. <i>Annual Review of Pharmacology and Toxicology</i> , 2014, 54, 381-405.	4.2	76
43	Synthesis of the Pitstop family of clathrin inhibitors. <i>Nature Protocols</i> , 2014, 9, 1592-1606.	5.5	32
44	Advances in Therapeutics for Neurodegenerative Tauopathies: Moving toward the Specific Targeting of the Most Toxic Tau Species. <i>ACS Chemical Neuroscience</i> , 2014, 5, 752-769.	1.7	63
45	Amplification of Tau Fibrils from Minute Quantities of Seeds. <i>Biochemistry</i> , 2014, 53, 5804-5809.	1.2	71
46	Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. <i>Nature Medicine</i> , 2014, 20, 130-138.	15.2	547
47	The Role of Tau Oligomers in the Onset of Alzheimer's Disease Neuropathology. <i>ACS Chemical Neuroscience</i> , 2014, 5, 1178-1191.	1.7	85
48	Acetylation: a new key to unlock tau's role in neurodegeneration. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 29.	3.0	101
49	Proteins Recruited to Exosomes by Tau Overexpression Implicate Novel Cellular Mechanisms Linking Tau Secretion with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 40, S47-S70.	1.2	57
50	Molecular Mechanisms of Protein Misfolding. , 2014, , 1-14.		2
51	Proteopathic tau seeding predicts tauopathy in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E4376-85.	3.3	474
52	Sources of Extracellular Tau and its Signaling. <i>Journal of Alzheimer's Disease</i> , 2014, 40, S7-S15.	1.2	27
53	Review: Prion-like mechanisms of transactive response DNA binding protein of 43 kDa (<sc>TDP</sc>-43) in amyotrophic lateral sclerosis (<sc>ALS</sc>). <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 578-597.	1.8	76
54	Starvation and inhibition of lysosomal function increased tau secretion by primary cortical neurons. <i>Scientific Reports</i> , 2014, 4, 5715.	1.6	77
55	Identification of disulfide cross-linked tau dimer responsible for tau propagation. <i>Scientific Reports</i> , 2015, 5, 15231.	1.6	51

#	ARTICLE	IF	CITATIONS
56	Tau Oligomers: The Toxic Player at Synapses in Alzheimer's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 464.	1.8	127
57	Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific Antibodies. <i>PLoS ONE</i> , 2015, 10, e0135774.	1.1	39
58	The role of macropinocytosis in the propagation of protein aggregation associated with neurodegenerative diseases. <i>Frontiers in Physiology</i> , 2015, 6, 277.	1.3	45
59	Extracellular association of APP and tau fibrils induces intracellular aggregate formation of tau. <i>Acta Neuropathologica</i> , 2015, 129, 895-907.	3.9	65
60	Targeting Assembly and Disassembly of Protein Aggregates. , 2015, , 173-228.		1
61	Isolation and characterization of antibody fragments selective for toxic oligomeric tau. <i>Neurobiology of Aging</i> , 2015, 36, 1342-1355.	1.5	25
62	Synaptic Contacts Enhance Cell-to-Cell Tau Pathology Propagation. <i>Cell Reports</i> , 2015, 11, 1176-1183.	2.9	206
63	Retromer in Alzheimer disease, Parkinson disease and other neurological disorders. <i>Nature Reviews Neuroscience</i> , 2015, 16, 126-132.	4.9	197
64	Conformation Determines the Seeding Potencies of Native and Recombinant Tau Aggregates. <i>Journal of Biological Chemistry</i> , 2015, 290, 1049-1065.	1.6	225
65	Spreading of pathology in neurodegenerative diseases: a focus on human studies. <i>Nature Reviews Neuroscience</i> , 2015, 16, 109-120.	4.9	611
66	The FK506-binding protein FKBP52 <i>in vitro</i> induces aggregation of truncated Tau forms with prion-like behavior. <i>FASEB Journal</i> , 2015, 29, 3171-3181.	0.2	33
67	Tau Trimers Are the Minimal Propagation Unit Spontaneously Internalized to Seed Intracellular Aggregation. <i>Journal of Biological Chemistry</i> , 2015, 290, 14893-14903.	1.6	182
68	Structural, morphological, and functional diversity of amyloid oligomers. <i>FEBS Letters</i> , 2015, 589, 2640-2648.	1.3	150
69	Sequence-dependent abnormal aggregation of human Tau fragment in an inducible cell model. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2015, 1852, 1561-1573.	1.8	12
70	<sc>TDP</sc> ⁴³ in amyotrophic lateral sclerosis " is it a prion disease?. <i>European Journal of Neurology</i> , 2015, 22, 753-761.	1.7	38
71	Animal models for prion-like diseases. <i>Virus Research</i> , 2015, 207, 5-24.	1.1	10
72	Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2015, 3, 14.	2.4	176
73	Tauopathy Mouse Models. , 2015, , 849-855.		0

#	ARTICLE	IF	CITATIONS
74	Assembly and Disassembly of Protein Aggregates. , 2015, , 229-276.		0
75	Neuronal Aggregates: Formation, Clearance, and Spreading. <i>Developmental Cell</i> , 2015, 32, 491-501.	3.1	185
76	Neurodegenerative Diseases: Expanding the Prion Concept. <i>Annual Review of Neuroscience</i> , 2015, 38, 87-103.	5.0	278
77	Tau Assembly: The Dominant Role of PHF6 (VQIVYK) in Microtubule Binding Region Repeat R3. <i>Journal of Physical Chemistry B</i> , 2015, 119, 4582-4593.	1.2	134
78	Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells. <i>Journal of Neuroscience</i> , 2015, 35, 14234-14250.	1.7	186
79	Genetics of Frontotemporal Dementia. , 2015, , 75-105.		0
80	Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer's disease brain. <i>Nature Communications</i> , 2015, 6, 8490.	5.8	283
81	The preclinical phase of the pathological process underlying sporadic Alzheimer's disease. <i>Brain</i> , 2015, 138, 2814-2833.	3.7	380
82	Configuration-specific immunotherapy targeting cis pThr231-Pro232 tau for Alzheimer disease. <i>Journal of the Neurological Sciences</i> , 2015, 348, 253-255.	0.3	11
83	An alkaline phosphatase transport mechanism in the pathogenesis of Alzheimer's disease and neurodegeneration. <i>Chemico-Biological Interactions</i> , 2015, 226, 30-39.	1.7	19
84	Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice. <i>Neurobiology of Disease</i> , 2015, 73, 83-95.	2.1	168
85	Do Astrocytes Collaborate with Neurons in Spreading the "Infectious" and Tau Drivers of Alzheimer's Disease?. <i>Neuroscientist</i> , 2015, 21, 9-29.	2.6	59
86	Ameliorative Effects of Antioxidants on the Hippocampal Accumulation of Pathologic Tau in a Rat Model of Blast-Induced Traumatic Brain Injury. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-15.	1.9	30
87	Internalization of the Extracellular Full-Length Tau Inside Neuro2A and Cortical Cells Is Enhanced by Phosphorylation. <i>Biomolecules</i> , 2016, 6, 36.	1.8	10
88	Uses and abuses of macropinocytosis. <i>Journal of Cell Science</i> , 2016, 129, 2697-705.	1.2	160
89	Peptides NAP and SAL attenuate human tau granular-shaped oligomers in vitro and in SH-SY5Y cells. <i>Neuropeptides</i> , 2016, 59, 21-31.	0.9	4
90	The Effect of Fragmented Pathogenic β -Synuclein Seeds on Prion-like Propagation. <i>Journal of Biological Chemistry</i> , 2016, 291, 18675-18688.	1.6	88
91	Internalized Tau sensitizes cells to stress by promoting formation and stability of stress granules. <i>Scientific Reports</i> , 2016, 6, 30498.	1.6	62

#	ARTICLE	IF	CITATIONS
92	Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1083-1099.	1.2	138
93	Î±-Synuclein and huntingtin exon 1 amyloid fibrils bind laterally to the cellular membrane. <i>Scientific Reports</i> , 2016, 6, 19180.	1.6	35
94	FRMD4A-cytohesin signaling modulates cellular release of Tau. <i>Journal of Cell Science</i> , 2016, 129, 2003-15.	1.2	27
95	The Dynamics and Turnover of Tau Aggregates in Cultured Cells. <i>Journal of Biological Chemistry</i> , 2016, 291, 13175-13193.	1.6	59
96	Fracture and Growth Are Competing Forces Determining the Fate of Conformers in Tau Fibril Populations. <i>Journal of Biological Chemistry</i> , 2016, 291, 12271-12281.	1.6	30
97	Molecular mechanism of prion-like tau-induced neurodegeneration. <i>Alzheimer's and Dementia</i> , 2016, 12, 1090-1097.	0.4	53
98	Formation, release, and internalization of stable tau oligomers in cells. <i>Journal of Neurochemistry</i> , 2016, 139, 1163-1174.	2.1	49
99	Potential mechanisms and implications for the formation of tau oligomeric strains. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2016, 51, 482-496.	2.3	64
100	Tunneling nanotubes: A possible highway in the spreading of tau and other prion-like proteins in neurodegenerative diseases. <i>Prion</i> , 2016, 10, 344-351.	0.9	151
101	High-Molecular-Weight Paired Helical Filaments from Alzheimer Brain Induces Seeding of Wild-Type Mouse Tau into an Argyrophilic 4R Tau Pathology in Vivo. <i>American Journal of Pathology</i> , 2016, 186, 2709-2722.	1.9	51
102	Prion-like propagation as a pathogenic principle in frontotemporal dementia. <i>Journal of Neurochemistry</i> , 2016, 138, 163-183.	2.1	54
103	Interactions between heme and tau-derived R1 peptides: binding and oxidative reactivity. <i>Dalton Transactions</i> , 2016, 45, 14343-14351.	1.6	9
104	Potential Pathways of Abnormal Tau and Î±-Synuclein Dissemination in Sporadic Alzheimer's and Parkinson's Diseases. <i>Cold Spring Harbor Perspectives in Biology</i> , 2016, 8, a023630.	2.3	101
105	Unique pathological tau conformers from Alzheimer's brains transmit tau pathology in nontransgenic mice. <i>Journal of Experimental Medicine</i> , 2016, 213, 2635-2654.	4.2	310
106	Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory. <i>Scientific Reports</i> , 2016, 6, 19393.	1.6	212
107	Loss of Bin1 Promotes the Propagation of Tau Pathology. <i>Cell Reports</i> , 2016, 17, 931-940.	2.9	206
108	Passive Immunotherapy for Tau Pathology. , 2016, , 371-384.		2
109	Neuronal activity enhances tau propagation and tau pathology in vivo. <i>Nature Neuroscience</i> , 2016, 19, 1085-1092.	7.1	569

#	ARTICLE	IF	CITATIONS
110	Chronic Repetitive Mild Traumatic Brain Injury Results in Reduced Cerebral Blood Flow, Axonal Injury, Gliosis, and Increased T-Tau and Tau Oligomers. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 636-655.	0.9	104
111	Tau Immunotherapy. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 109-120.	0.1	1
112	Detecting tau in serum of transgenic animal models after tau immunotherapy treatment. <i>Neurobiology of Aging</i> , 2016, 37, 58-65.	1.5	16
113	Structural differences between amyloid beta oligomers. <i>Biochemical and Biophysical Research Communications</i> , 2016, 477, 700-705.	1.0	65
114	Short Fibrils Constitute the Major Species of Seed-Competent Tau in the Brains of Mice Transgenic for Human P301S Tau. <i>Journal of Neuroscience</i> , 2016, 36, 762-772.	1.7	129
115	Tau Oligomers Derived from Traumatic Brain Injury Cause Cognitive Impairment and Accelerate Onset of Pathology in Htau Mice. <i>Journal of Neurotrauma</i> , 2016, 33, 2034-2043.	1.7	75
116	Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. <i>Acta Neuropathologica</i> , 2016, 131, 27-48.	3.9	147
117	Internalization of tau antibody and pathological tau protein detected with a flow cytometry multiplexing approach. , 2016, 12, 1098-1107.		29
118	Tau pathology-mediated presynaptic dysfunction. <i>Neuroscience</i> , 2016, 325, 30-38.	1.1	54
119	Prions and Protein Assemblies that Convey Biological Information in Health and Disease. <i>Neuron</i> , 2016, 89, 433-448.	3.8	74
120	Axonal transport and secretion of fibrillar forms of α -synuclein, A β 242 peptide and HTTExon 1. <i>Acta Neuropathologica</i> , 2016, 131, 539-548.	3.9	127
121	Protein aggregates stimulate macropinocytosis facilitating their propagation. <i>Prion</i> , 2016, 10, 119-126.	0.9	20
122	Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. <i>Nature Medicine</i> , 2016, 22, 46-53.	15.2	352
123	Spin Labeling and Characterization of Tau Fibrils Using Electron Paramagnetic Resonance (EPR). <i>Methods in Molecular Biology</i> , 2016, 1345, 185-199.	0.4	6
124	The Role of Retromer in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2016, 53, 4201-4209.	1.9	13
125	The release and trans-synaptic transmission of Tau via exosomes. <i>Molecular Neurodegeneration</i> , 2017, 12, 5.	4.4	475
126	Astrocyte transport of glutamate and neuronal activity reciprocally modulate tau pathology in <i>Drosophila</i> . <i>Neuroscience</i> , 2017, 348, 191-200.	1.1	19
127	PET Imaging Agents for Alzheimer's Disease. <i>Topics in Medicinal Chemistry</i> , 2017, , 181-197.	0.4	0

#	ARTICLE	IF	CITATIONS
128	Energy and the Alzheimer brain. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 75, 297-313.	2.9	32
129	Clinical correlates to assist with chronic traumatic encephalopathy diagnosis. <i>Journal of Trauma and Acute Care Surgery</i> , 2017, 82, 1039-1048.	1.1	11
130	The multitude of therapeutic targets in neurodegenerative proteinopathies. , 2017, , 1-20.		1
131	Preclinical models of Alzheimer's disease for identification and preclinical validation of therapeutic targets: from fine-tuning strategies for validated targets to new venues for therapy. , 2017, , 115-156.		2
132	Extracellular Tau Oligomers Induce Invasion of Endogenous Tau into the Somatodendritic Compartment and Axonal Transport Dysfunction. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 803-820.	1.2	51
133	Selective imaging of internalized proteopathic β -synuclein seeds in primary neurons reveals mechanistic insight into transmission of synucleinopathies. <i>Journal of Biological Chemistry</i> , 2017, 292, 13482-13497.	1.6	131
134	Spreading of Pathology in Alzheimer's Disease. <i>Neurotoxicity Research</i> , 2017, 32, 707-722.	1.3	13
135	Reduced gliotransmitter release from astrocytes mediates tau-induced synaptic dysfunction in cultured hippocampal neurons. <i>Glia</i> , 2017, 65, 1302-1316.	2.5	82
136	Roles of tau protein in health and disease. <i>Acta Neuropathologica</i> , 2017, 133, 665-704.	3.9	639
137	Chronic Traumatic Encephalopathy: The cellular sequela to repetitive brain injury. <i>Journal of Clinical Neuroscience</i> , 2017, 41, 24-29.	0.8	18
139	Novel Cell Model for Tauopathy Induced by a Cell-Permeable Tau-Related Peptide. <i>ACS Chemical Neuroscience</i> , 2017, 8, 2734-2745.	1.7	11
140	Amyloidogenesis of Tau protein. <i>Protein Science</i> , 2017, 26, 2126-2150.	3.1	102
141	Chronic traumatic encephalopathy-integration of canonical traumatic brain injury secondary injury mechanisms with tau pathology. <i>Progress in Neurobiology</i> , 2017, 158, 15-44.	2.8	48
142	The spread of prion-like proteins by lysosomes and tunneling nanotubes: Implications for neurodegenerative diseases. <i>Journal of Cell Biology</i> , 2017, 216, 2633-2644.	2.3	105
143	Prion strains depend on different endocytic routes for productive infection. <i>Scientific Reports</i> , 2017, 7, 6923.	1.6	29
144	Abolishing Tau cleavage by caspases at Aspartate421 causes memory/synaptic plasticity deficits and pre-pathological Tau alterations. <i>Translational Psychiatry</i> , 2017, 7, e1198-e1198.	2.4	19
145	Discovery and characterization of stable and toxic Tau/phospholipid oligomeric complexes. <i>Nature Communications</i> , 2017, 8, 1678.	5.8	117
146	Glial contributions to neurodegeneration in tauopathies. <i>Molecular Neurodegeneration</i> , 2017, 12, 50.	4.4	283

#	ARTICLE	IF	CITATIONS
147	Oligomer Formation and Cross-Seed: The New Frontier. <i>Israel Journal of Chemistry</i> , 2017, 57, 665-673.	1.0	8
149	Like prions: the propagation of aggregated tau and β -synuclein in neurodegeneration. <i>Brain</i> , 2017, 140, 266-278.	3.7	248
150	<sc>VCP</sc> /p97 cooperates with <sc>YOD</sc> 1, <sc>UBXD</sc> 1 and <sc>PLAA</sc> to drive clearance of ruptured lysosomes by autophagy. <i>EMBO Journal</i> , 2017, 36, 135-150.	3.5	259
151	Cellular Models for the Study of Prions. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a024026.	2.9	18
152	Tauopathies: Mechanisms and Therapeutic Strategies. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 487-508.	1.2	19
153	Prelysosomal Compartments in the Unconventional Secretion of Amyloidogenic Seeds. <i>International Journal of Molecular Sciences</i> , 2017, 18, 227.	1.8	24
154	Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 83.	1.7	209
155	Amyloid β -Exposed Human Astrocytes Overproduce Phospho-Tau and Overrelease It within Exosomes, Effects Suppressed by Calcilytic NPS 2143â€”Further Implications for Alzheimer's Therapy. <i>Frontiers in Neuroscience</i> , 2017, 11, 217.	1.4	88
156	The Evidence for the Spread and Seeding Capacities of the Mutant Huntingtin Protein in in Vitro Systems and Their Therapeutic Implications. <i>Frontiers in Neuroscience</i> , 2017, 11, 647.	1.4	33
157	The Potential of Small Molecules in Preventing Tau Oligomer Formation and Toxicity. , 2017, , 97-121.		3
158	Down but Not Out: The Consequences of Pretangle Tau in the Locus Coeruleus. <i>Neural Plasticity</i> , 2017, 2017, 1-9.	1.0	39
159	Tau secretion is correlated to an increase of Golgi dynamics. <i>PLoS ONE</i> , 2017, 12, e0178288.	1.1	40
160	Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease. <i>Chinese Medical Journal</i> , 2017, 130, 2978-2990.	0.9	49
161	LTP and memory impairment caused by extracellular $A\beta$ and Tau oligomers is APP-dependent. <i>ELife</i> , 2017, 6, .	2.8	121
162	Prion-like properties of disease-relevant proteins in amyotrophic lateral sclerosis. <i>Journal of Neural Transmission</i> , 2018, 125, 591-613.	1.4	16
163	Galectin-8â€”mediated selective autophagy protects against seeded tau aggregation. <i>Journal of Biological Chemistry</i> , 2018, 293, 2438-2451.	1.6	84
164	Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies. <i>Journal of Biological Chemistry</i> , 2018, 293, 2408-2421.	1.6	103
165	The interactions of p53 with tau and $A\beta$ as potential therapeutic targets for Alzheimer's disease. <i>Progress in Neurobiology</i> , 2018, 168, 104-127.	2.8	74

#	ARTICLE	IF	CITATIONS
166	Extracellular Monomeric and Aggregated Tau Efficiently Enter Human Neurons through Overlapping but Distinct Pathways. <i>Cell Reports</i> , 2018, 22, 3612-3624.	2.9	147
167	Microfluidic approaches for probing amyloid assembly and behaviour. <i>Lab on A Chip</i> , 2018, 18, 999-1016.	3.1	27
168	Amyloid- β^2 and tau complexity " towards improved biomarkers and targeted therapies. <i>Nature Reviews Neurology</i> , 2018, 14, 22-39.	4.9	303
169	Functional interplay between plasma membrane Ca ²⁺ -ATPase, amyloid β^2 -peptide and tau. <i>Neuroscience Letters</i> , 2018, 663, 55-59.	1.0	20
170	Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. <i>Nature Neuroscience</i> , 2018, 21, 1341-1349.	7.1	289
171	Passive Immunotherapy in Alzheimer's Disease. , 0, , .		2
172	Tau: A Common Denominator and Therapeutic Target for Neurodegenerative Disorders. <i>Journal of Experimental Neuroscience</i> , 2018, 12, 117906951877238.	2.3	9
173	Unconventional Secretion Mediates the Trans-cellular Spreading of Tau. <i>Cell Reports</i> , 2018, 23, 2039-2055.	2.9	194
174	Secretion of full-length Tau or Tau fragments in cell culture models. Propagation of Tau in vivo and in vitro. <i>Biomolecular Concepts</i> , 2018, 9, 1-11.	1.0	14
175	Ways to stop the spread of Alzheimer's disease. <i>Nature</i> , 2018, 559, S16-S17.	13.7	5
176	The Role of Microglia in the Spread of Tau: Relevance for Tauopathies. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 172.	1.8	92
177	Intercellular Spread of Protein Aggregates in Neurodegenerative Disease. <i>Annual Review of Cell and Developmental Biology</i> , 2018, 34, 545-568.	4.0	99
178	Synaptic Tau Seeding Precedes Tau Pathology in Human Alzheimer's Disease Brain. <i>Frontiers in Neuroscience</i> , 2018, 12, 267.	1.4	198
179	Prion-Like Propagation of Post-Translationally Modified Tau in Alzheimer's Disease: A Hypothesis. <i>Journal of Molecular Neuroscience</i> , 2018, 65, 480-490.	1.1	52
180	A common antigenic motif recognized by naturally occurring human VH5"51/VL4"1 anti-tau antibodies with distinct functionalities. <i>Acta Neuropathologica Communications</i> , 2018, 6, 43.	2.4	15
181	Tau Spreading Mechanisms; Implications for Dysfunctional Tauopathies. <i>International Journal of Molecular Sciences</i> , 2018, 19, 645.	1.8	36
182	Transcellular Spreading of Tau in Tauopathies. <i>ChemBioChem</i> , 2018, 19, 2424-2432.	1.3	22
183	Soluble tau aggregates, not large fibrils, are the toxic species that display seeding and cross-seeding behavior. <i>Protein Science</i> , 2018, 27, 1901-1909.	3.1	88

#	ARTICLE	IF	CITATIONS
184	Role of Amyloid- β^2 and Tau Proteins in Alzheimer's Disease: Confuting the Amyloid Cascade. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S611-S631.	1.2	102
185	Prion-like mechanisms in Alzheimer disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and C W Bruyn, 2018, 153, 303-319.	1.0	42
186	First-in-Rat Study of Human Alzheimer's Disease Tau Propagation. <i>Molecular Neurobiology</i> , 2019, 56, 621-631.	1.9	21
187	Endosomal sorting and trafficking, the retromer complex and neurodegeneration. <i>Molecular Psychiatry</i> , 2019, 24, 857-868.	4.1	59
188	Progression of Alzheimer's disease, tau propagation, and its modifiable risk factors. <i>Neuroscience Research</i> , 2019, 141, 36-42.	1.0	50
189	Therapeutic antibody targeting microtubule-binding domain prevents neuronal internalization of extracellular tau via masking neuron surface proteoglycans. <i>Acta Neuropathologica Communications</i> , 2019, 7, 129.	2.4	32
190	Unilateral Focused Ultrasound-Induced Blood-Brain Barrier Opening Reduces Phosphorylated Tau from The rTg4510 Mouse Model. <i>Theranostics</i> , 2019, 9, 5396-5411.	4.6	63
191	Tau Secretion: Good and Bad for Neurons. <i>Frontiers in Neuroscience</i> , 2019, 13, 649.	1.4	39
192	Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric A β^2 and Tau Species. <i>Frontiers in Neuroscience</i> , 2019, 13, 659.	1.4	198
193	Distinct Conformations, Aggregation and Cellular Internalization of Different Tau Strains. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 296.	1.8	36
194	Synaptic and memory dysfunction induced by tau oligomers is rescued by up-regulation of the nitric oxide cascade. <i>Molecular Neurodegeneration</i> , 2019, 14, 26.	4.4	59
195	Autophagy-Mediated Secretory Pathway is Responsible for Both Normal and Pathological Tau in Neurons. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 667-680.	1.2	36
196	Intersection of pathological tau and microglia at the synapse. <i>Acta Neuropathologica Communications</i> , 2019, 7, 109.	2.4	119
197	Dynamic structural determinants underlie the neurotoxicity of the N-terminal tau 26-44 peptide in Alzheimer's disease and other human tauopathies. <i>International Journal of Biological Macromolecules</i> , 2019, 141, 278-289.	3.6	16
198	Tau Misfolding Efficiently Propagates between Individual Intact Hippocampal Neurons. <i>Journal of Neuroscience</i> , 2019, 39, 9623-9632.	1.7	34
199	Quantification of Tau Protein Lysine Methylation in Aging and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 979-991.	1.2	39
200	Normal and Pathological Tau Uptake Mediated by M1/M3 Muscarinic Receptors Promotes Opposite Neuronal Changes. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 403.	1.8	43
201	Asparagine endopeptidase cleaves tau at N167 after uptake into microglia. <i>Neurobiology of Disease</i> , 2019, 130, 104518.	2.1	17

#	ARTICLE	IF	CITATIONS
202	Extracellular β -synuclein enters dopaminergic cells by modulating flotillin α -assisted dopamine transporter endocytosis. <i>FASEB Journal</i> , 2019, 33, 10240-10256.	0.2	16
203	Four-repeat tauopathies. <i>Progress in Neurobiology</i> , 2019, 180, 101644.	2.8	141
204	Cerebrospinal fluid from Alzheimer's disease patients promotes tau aggregation in transgenic mice. <i>Acta Neuropathologica Communications</i> , 2019, 7, 72.	2.4	16
205	Spreading of β -Synuclein and Tau: A Systematic Comparison of the Mechanisms Involved. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 107.	1.4	79
206	The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory. <i>Nature Communications</i> , 2019, 10, 1766.	5.8	68
207	An acetylation mimicking mutation, K274Q, in tau imparts neurotoxicity by enhancing tau aggregation and inhibiting tubulin polymerization. <i>Biochemical Journal</i> , 2019, 476, 1401-1417.	1.7	29
208	Mechanistic approaches to understand the prion-like propagation of aggregates of the human tau protein. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2019, 1867, 922-932.	1.1	8
209	The complexity of tau in Alzheimer's disease. <i>Neuroscience Letters</i> , 2019, 705, 183-194.	1.0	200
210	Prion and Prion-Like Protein Strains: Deciphering the Molecular Basis of Heterogeneity in Neurodegeneration. <i>Viruses</i> , 2019, 11, 261.	1.5	41
211	Dural lymphatics regulate clearance of extracellular tau from the CNS. <i>Molecular Neurodegeneration</i> , 2019, 14, 11.	4.4	134
212	Propagation of Protein Aggregation in Neurodegenerative Diseases. <i>Annual Review of Biochemistry</i> , 2019, 88, 785-810.	5.0	213
213	Multi-compartment Microfluidic Device Geometry and Covalently Bound Poly-D-Lysine Influence Neuronal Maturation. <i>Frontiers in Bioengineering and Biotechnology</i> , 2019, 7, 84.	2.0	17
214	A walk through tau therapeutic strategies. <i>Acta Neuropathologica Communications</i> , 2019, 7, 22.	2.4	211
215	The role of annealing and fragmentation in human tau aggregation dynamics. <i>Journal of Biological Chemistry</i> , 2019, 294, 4728-4737.	1.6	14
216	The gut-brain axis in the pathogenesis of Parkinson's disease. <i>Brain Science Advances</i> , 2019, 5, 73-81.	0.3	10
217	Tau Propagation as a Diagnostic and Therapeutic Target for Dementia: Potentials and Unanswered Questions. <i>Frontiers in Neuroscience</i> , 2019, 13, 1274.	1.4	32
218	Seeding Activity-Based Detection Uncovers the Different Release Mechanisms of Seed-Competent Tau Versus Inert Tau via Lysosomal Exocytosis. <i>Frontiers in Neuroscience</i> , 2019, 13, 1258.	1.4	14
219	Mechanisms of Cell-to-Cell Transmission of Pathological Tau. <i>JAMA Neurology</i> , 2019, 76, 101.	4.5	162

#	ARTICLE	IF	CITATIONS
220	A tau homeostasis signature is linked with the cellular and regional vulnerability of excitatory neurons to tau pathology. <i>Nature Neuroscience</i> , 2019, 22, 47-56.	7.1	154
221	Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies. , 2019, 195, 186-198.		141
222	Amyloid-beta induced retrograde axonal degeneration in a mouse tauopathy model. <i>NeuroImage</i> , 2019, 189, 180-191.	2.1	23
223	Pathological Changes of Tau Related to Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2019, 10, 931-944.	1.7	54
224	Minimalistic in vitro systems for investigating tau pathology. <i>Journal of Neuroscience Methods</i> , 2019, 319, 69-76.	1.3	3
225	Evidence of corticofugal tau spreading in patients with frontotemporal dementia. <i>Acta Neuropathologica</i> , 2020, 139, 27-43.	3.9	29
226	Propagation of Tau Pathology: Integrating Insights From Postmortem and In Vivo Studies. <i>Biological Psychiatry</i> , 2020, 87, 808-818.	0.7	50
227	Sulfation of Heparan Sulfate Enhances Tau Interaction and Cellular Uptake. <i>Angewandte Chemie</i> , 2020, 132, 1834-1843.	1.6	2
228	Mechanisms of secretion and spreading of pathological tau protein. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 1721-1744.	2.4	174
229	Sulfation of Heparan Sulfate Enhances Tau Interaction and Cellular Uptake. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 1818-1827.	7.2	71
230	From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy. <i>Acta Neuropathologica</i> , 2020, 139, 3-25.	3.9	134
231	Familial globular glial tauopathy linked to MAPT mutations: molecular neuropathology and seeding capacity of a prototypical mixed neuronal and glial tauopathy. <i>Acta Neuropathologica</i> , 2020, 139, 735-771.	3.9	35
232	Picalm reduction exacerbates tau pathology in a murine tauopathy model. <i>Acta Neuropathologica</i> , 2020, 139, 773-789.	3.9	27
233	Extracellular tau induces microglial phagocytosis of living neurons in cell cultures. <i>Journal of Neurochemistry</i> , 2020, 154, 316-329.	2.1	35
234	Advances and considerations in AD tau-targeted immunotherapy. <i>Neurobiology of Disease</i> , 2020, 134, 104707.	2.1	70
235	Potential of Microfluidics and Lab-on-Chip Platforms to Improve Understanding of Prion-like Protein Assembly and Behavior. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 570692.	2.0	5
236	Microglia in Alzheimer's Disease in the Context of Tau Pathology. <i>Biomolecules</i> , 2020, 10, 1439.	1.8	56
237	The Cell Biology of Tau Secretion. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 569818.	1.4	28

#	ARTICLE	IF	CITATIONS
238	New Strategy for Reducing Tau Aggregation Cytologically by A Hairpinlike Molecular Inhibitor, Tannic Acid Encapsulated in Liposome. <i>ACS Chemical Neuroscience</i> , 2020, 11, 3623-3634.	1.7	14
239	Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2020, 15, 40.	4.4	438
240	Paired Helical Filament-Forming Region of Tau (297-391) Influences Endogenous Tau Protein and Accumulates in Acidic Compartments in Human Neuronal Cells. <i>Journal of Molecular Biology</i> , 2020, 432, 4891-4907.	2.0	15
241	Tau Protein as a New Regulator of Cellular Prion Protein Transcription. <i>Molecular Neurobiology</i> , 2020, 57, 4170-4186.	1.9	6
242	Pharmacological Modulators of Tau Aggregation and Spreading. <i>Brain Sciences</i> , 2020, 10, 858.	1.1	17
243	Targeting Tau to Treat Clinical Features of Huntington's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 580732.	1.1	13
244	Fate and propagation of endogenously formed Tau aggregates in neuronal cells. <i>EMBO Molecular Medicine</i> , 2020, 12, e12025.	3.3	41
245	Comparison of size distribution and (Pro249-Ser258) epitope exposure in in vitro and in vivo derived Tau fibrils. <i>BMC Molecular and Cell Biology</i> , 2020, 21, 81.	1.0	3
246	Dynamics of Internalization and Intracellular Interaction of Tau Antibodies and Human Pathological Tau Protein in a Human Neuron-Like Model. <i>Frontiers in Neurology</i> , 2020, 11, 602292.	1.1	10
247	Tau Filament Self-Assembly and Structure: Tau as a Therapeutic Target. <i>Frontiers in Neurology</i> , 2020, 11, 590754.	1.1	32
248	Periarterial pathways for clearance of α -Synuclein and tau from the brain: Implications for the pathogenesis of dementias and for immunotherapy. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12070.	1.2	17
249	Role of tau protein in Alzheimer's disease: The prime pathological player. <i>International Journal of Biological Macromolecules</i> , 2020, 163, 1599-1617.	3.6	100
250	Quantitative propagation of assembled human Tau from Alzheimer's disease brain in microfluidic neuronal cultures. <i>Journal of Biological Chemistry</i> , 2020, 295, 13079-13093.	1.6	22
251	Repetitive Head Trauma Induces Chronic Traumatic Encephalopathy by Multiple Mechanisms. <i>Seminars in Neurology</i> , 2020, 40, 430-438.	0.5	10
252	Prion-Like Propagation Mechanisms in Tauopathies and Traumatic Brain Injury: Challenges and Prospects. <i>Biomolecules</i> , 2020, 10, 1487.	1.8	5
253	Degradation and Transmission of Tau by Autophagic-Endolysosomal Networks and Potential Therapeutic Targets for Tauopathy. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 586731.	1.4	56
254	Intramuscular injection of vectorized-scFvMC1 reduces pathological tau in two different tau transgenic models. <i>Acta Neuropathologica Communications</i> , 2020, 8, 126.	2.4	5
255	Principal components of tau positron emission tomography and longitudinal tau accumulation in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 114.	3.0	8

#	ARTICLE	IF	CITATIONS
256	Tau proteinopathies and the prion concept. <i>Progress in Molecular Biology and Translational Science</i> , 2020, 175, 239-259.	0.9	20
257	Microfluidics-Based Systems in Diagnosis of Alzheimer's Disease and Biomimetic Modeling. <i>Micromachines</i> , 2020, 11, 787.	1.4	18
258	Aggrecan modulates the expression and phosphorylation of tau in a novel bigenic TauP301L <i>Aggrecan</i> mouse model. <i>European Journal of Neuroscience</i> , 2021, 53, 3889-3904.	1.2	5
259	Mechanisms of Pathogenic Tau and A β Protein Spreading in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 265.	1.7	78
260	The uptake of tau amyloid fibrils is facilitated by the cellular prion protein and hampers prion propagation in cultured cells. <i>Journal of Neurochemistry</i> , 2020, 155, 577-591.	2.1	32
261	The involvement of stress granules in aging and aging-associated diseases. <i>Aging Cell</i> , 2020, 19, e13136.	3.0	68
262	Protein transmission in neurodegenerative disease. <i>Nature Reviews Neurology</i> , 2020, 16, 199-212.	4.9	330
263	Role of dietary fatty acids in microglial polarization in Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2020, 17, 93.	3.1	57
264	Capacity for Seeding and Spreading of Argyrophilic Grain Disease in a Wild-Type Murine Model; Comparisons With Primary Age-Related Tauopathy. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 101.	1.4	8
265	Intracerebral seeding of amyloid- β and tau pathology in mice: Factors underlying prion-like spreading and comparisons with α -synuclein. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 112, 1-27.	2.9	31
266	Prion-like properties of Tau assemblies. <i>Current Opinion in Neurobiology</i> , 2020, 61, 49-57.	2.0	20
267	Pharmacological inhibition and knockdown of O-GlcNAcase reduces cellular internalization of α -synuclein preformed fibrils. <i>FEBS Journal</i> , 2021, 288, 452-470.	2.2	28
268	Knockin on heaven's door: Molecular mechanisms of neuronal tau uptake. <i>Journal of Neurochemistry</i> , 2021, 156, 563-588.	2.1	14
269	α -Synuclein abnormalities trigger focal tau pathology, spreading to various brain areas in Parkinson disease. <i>Journal of Neurochemistry</i> , 2021, 157, 727-751.	2.1	13
270	Alzheimer's Disease: Tau Pathology and Dysfunction of Endocytosis. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 583755.	1.4	19
271	Indication of retrograde tau spreading along Braak stages and functional connectivity pathways. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2272-2282.	3.3	12
272	PIKfyve activity is required for lysosomal trafficking of tau aggregates and tau seeding. <i>Journal of Biological Chemistry</i> , 2021, 296, 100636.	1.6	21
273	Filamentous recombinant human Tau activates primary astrocytes via an integrin receptor complex. <i>Nature Communications</i> , 2021, 12, 95.	5.8	46

#	ARTICLE	IF	CITATIONS
274	Impact of Tau on Neurovascular Pathology in Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 573324.	1.1	24
275	Quantifying misfolded protein oligomers as drug targets and biomarkers in Alzheimer and Parkinson diseases. <i>Nature Reviews Chemistry</i> , 2021, 5, 277-294.	13.8	56
276	Advances in microfluidic <i>in vitro</i> systems for neurological disease modeling. <i>Journal of Neuroscience Research</i> , 2021, 99, 1276-1307.	1.3	56
277	Critical Molecular and Cellular Contributors to Tau Pathology. <i>Biomedicines</i> , 2021, 9, 190.	1.4	26
278	Seizures are a druggable mechanistic link between TBI and subsequent tauopathy. <i>ELife</i> , 2021, 10, .	2.8	22
280	The propagation mechanisms of extracellular tau in Alzheimer's disease. <i>Journal of Neurology</i> , 2022, 269, 1164-1181.	1.8	10
281	Tau internalization: A complex step in tau propagation. <i>Ageing Research Reviews</i> , 2021, 67, 101272.	5.0	18
282	Graph Models of Pathology Spread in Alzheimer's Disease: An Alternative to Conventional Graph Theoretic Analysis. <i>Brain Connectivity</i> , 2021, 11, 799-814.	0.8	9
283	Emerging Brain Pathophysiology Mimetic Platforms for Studying Neurodegenerative Diseases: Brain Organoids and Brains-on-a-Chip. <i>Advanced Healthcare Materials</i> , 2021, 10, e2002119.	3.9	27
284	Role of the endolysosomal pathway and exosome release in tau propagation. <i>Neurochemistry International</i> , 2021, 145, 104988.	1.9	9
285	Development of P301S tau seeded organotypic hippocampal slice cultures to study potential therapeutics. <i>Scientific Reports</i> , 2021, 11, 10309.	1.6	2
287	Tau Seeding Mouse Models with Patient Brain-Derived Aggregates. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6132.	1.8	14
288	Sorcín Activates the Brain PMCA and Blocks the Inhibitory Effects of Molecular Markers of Alzheimer's Disease on the Pump Activity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6055.	1.8	9
290	Lysosome dysfunction as a cause of neurodegenerative diseases: Lessons from frontotemporal dementia and amyotrophic lateral sclerosis. <i>Neurobiology of Disease</i> , 2021, 154, 105360.	2.1	101
291	The potential role of glial cells in driving the prion-like transcellular propagation of tau in tauopathies. <i>Brain, Behavior, & Immunity - Health</i> , 2021, 14, 100242.	1.3	14
292	Possible Mechanisms of Tau Spread and Toxicity in Alzheimer's Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 707268.	1.8	41
294	Accumulation of C-terminal cleaved tau is distinctly associated with cognitive deficits, synaptic plasticity impairment, and neurodegeneration in aged mice. <i>GeroScience</i> , 2022, 44, 173-194.	2.1	6
295	Astrocytes in Neurodegenerative Diseases: A Perspective from Tauopathy and α -Synucleinopathy. <i>Life</i> , 2021, 11, 938.	1.1	13

#	ARTICLE	IF	CITATIONS
296	Synaptic tau: A pathological or physiological phenomenon?. <i>Acta Neuropathologica Communications</i> , 2021, 9, 149.	2.4	30
297	Proteopathic tau primes and activates interleukin-1 β via myeloid-cell-specific MyD88- and NLRP3-ASC-inflammasome pathway. <i>Cell Reports</i> , 2021, 36, 109720.	2.9	42
298	Tau secretion and propagation: Perspectives for potential preventive interventions in Alzheimer's disease and other tauopathies. <i>Experimental Neurology</i> , 2021, 343, 113756.	2.0	18
299	Neurotoxicity of oligomers of phosphorylated Tau protein carrying tauopathy-associated mutation is inhibited by prion protein. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166209.	1.8	8
300	Tau Oligomers Neurotoxicity. <i>Life</i> , 2021, 11, 28.	1.1	42
301	Tau Secretion. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1184, 123-134.	0.8	13
302	Tau Prion-Like Propagation: State of the Art and Current Challenges. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1184, 305-325.	0.8	47
303	Liquid-Liquid Phase Separation of Tau Protein in Neurobiology and Pathology. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1184, 341-357.	0.8	13
304	Distinct Neurotoxic Effects of Extracellular Tau Species in Primary Neuronal-Glial Cultures. <i>Molecular Neurobiology</i> , 2021, 58, 658-667.	1.9	16
305	Internalization mechanisms of brain-derived tau oligomers from patients with Alzheimer's disease, progressive supranuclear palsy and dementia with Lewy bodies. <i>Cell Death and Disease</i> , 2020, 11, 314.	2.7	56
311	Tau is not necessary for amyloid- β -induced synaptic and memory impairments. <i>Journal of Clinical Investigation</i> , 2020, 130, 4831-4844.	3.9	34
312	Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy Models. <i>PLoS ONE</i> , 2015, 10, e0125614.	1.1	124
313	Detection of mis-folded protein aggregates from a clinical perspective. <i>Journal of Clinical and Translational Research</i> , 2016, 2, .	0.3	2
314	Prion-like Mechanisms in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2014, 11, 755-764.	0.7	27
315	Dangerous Liaisons: Tau Interaction with Muscarinic Receptors. <i>Current Alzheimer Research</i> , 2020, 17, 224-237.	0.7	12
316	Phagocytic glia are obligatory intermediates in transmission of mutant huntingtin aggregates across neuronal synapses. <i>ELife</i> , 2020, 9, .	2.8	24
317	Tau Post-Translational Modifications: Potentiators of Selective Vulnerability in Sporadic Alzheimer's Disease. <i>Biology</i> , 2021, 10, 1047.	1.3	14
318	Dynamic-Inspired Perspective on the Molecular Inhibitor of Tau Aggregation by Glucose Gallates Based on Human Neurons. <i>ACS Chemical Neuroscience</i> , 2021, 12, 4162-4174.	1.7	6

#	ARTICLE	IF	CITATIONS
319	Influence of traumatic brain injury on extracellular tau elimination at the blood-brain barrier. <i>Fluids and Barriers of the CNS</i> , 2021, 18, 48.	2.4	8
320	Tau Pathology in Neurodegenerative Diseases. <i>Neuromethods</i> , 2022, , 71-97.	0.2	1
321	Report from the Tau Front: Cantoblanco 2013. , 2014, 04, .		0
322	Frequent and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic terminals in Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2014, 2, 146.	2.4	60
323	Uncovering the Path to Neurodegeneration from Playingfield to Battlefield. , 0, , .		0
324	Prions et transconformation protéique: une perspective historique. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2015, 199, 787-796.	0.0	0
326	Prion-Like Propagation in Neurodegenerative Diseases. , 2018, , 189-242.		0
328	Proteopathic Tau Primes and Activates Interleukin-1 β (IL-1 β) via MyD88- and NLRP3-ASC-Inflammasome Dependent Pathways. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
331	Prion-like properties of the mutant huntingtin protein in living organisms: the evidence and the relevance. <i>Molecular Psychiatry</i> , 2022, 27, 269-280.	4.1	6
332	Editorial: Tau Protein: Mechanisms From Health to Degeneration. <i>Frontiers in Molecular Neuroscience</i> , 2021, 14, 743986.	1.4	0
334	The role of wild-type tau in Alzheimer's disease and related tauopathies. <i>Journal of Life Sciences (Westlake Village, Calif)</i> , 2020, 2, 1-17.	1.8	3
335	Co-culture of Murine Neurons Using a Microfluidic Device for The Study of Tau Misfolding Propagation. <i>Bio-protocol</i> , 2020, 10, e3718.	0.2	1
336	P62 accumulates through neuroanatomical circuits in response to tauopathy propagation. <i>Acta Neuropathologica Communications</i> , 2021, 9, 177.	2.4	8
337	Detection of misfolded protein aggregates from a clinical perspective. <i>Journal of Clinical and Translational Research</i> , 2016, 2, 11-26.	0.3	3
338	The formation of small aggregates contributes to the neurotoxic effects of tau45-230. <i>Neurochemistry International</i> , 2022, 152, 105252.	1.9	4
339	Revisit the Cellular Transmission and Emerging Techniques in Understanding the Mechanisms of Proteinopathies. <i>Frontiers in Neuroscience</i> , 2021, 15, 781722.	1.4	1
340	Proliferation of Tau 304-380 Fragment Aggregates through Autocatalytic Secondary Nucleation. <i>ACS Chemical Neuroscience</i> , 2021, 12, 4406-4415.	1.7	19
341	Alpha adaptins show isoform-specific association with neurofibrillary tangles in Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	1.8	6

#	ARTICLE	IF	CITATIONS
342	Nasal Rifampicin Halts the Progression of Tauopathy by Inhibiting Tau Oligomer Propagation in Alzheimer Brain Extract-Injected Mice. <i>Biomedicines</i> , 2022, 10, 297.	1.4	7
343	Heparan Sulfate Proteoglycans (HSPGs) Serve as the Mediator Between Monomeric Tau and Its Subsequent Intracellular ERK1/2 Pathway Activation. <i>Journal of Molecular Neuroscience</i> , 2022, 72, 772-791.	1.1	12
345	p38 Inhibition Decreases Tau Toxicity in Microglia and Improves Their Phagocytic Function. <i>Molecular Neurobiology</i> , 2022, 59, 1632-1648.	1.9	6
346	p38 activation occurs mainly in microglia in the P301S Tauopathy mouse model. <i>Scientific Reports</i> , 2022, 12, 2130.	1.6	5
347	Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease. <i>EBioMedicine</i> , 2022, 76, 103836.	2.7	65
348	Propagation of tau and α -synuclein in the brain: therapeutic potential of the glymphatic system. <i>Translational Neurodegeneration</i> , 2022, 11, 19.	3.6	15
350	Deciphering the prion-like behavior of pathogenic protein aggregates in neurodegenerative diseases. <i>Neurochemistry International</i> , 2022, 155, 105307.	1.9	5
351	Impaired Retromer Function in Niemann-Pick Type C Disease Is Dependent on Intracellular Cholesterol Accumulation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13256.	1.8	9
352	Amyloid β , Tau, and α -Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases. <i>Progress in Neurobiology</i> , 2022, 214, 102270.	2.8	77
372	Cholesterol determines the cytosolic entry and seeded aggregation of tau. <i>Cell Reports</i> , 2022, 39, 110776.	2.9	19
374	Hyperphosphorylated tau self-assembles into amorphous aggregates eliciting TLR4-dependent responses. <i>Nature Communications</i> , 2022, 13, 2692.	5.8	21
376	Modeling Neurodegenerative Diseases Using In Vitro Compartmentalized Microfluidic Devices. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	11
377	Axonal transport impairment and its relationship with diffusion tensor imaging metrics of a murine model of p301L tau induced tauopathy. <i>Neuroscience</i> , 2022, , .	1.1	2
378	The Fate of Tau Aggregates Between Clearance and Transmission. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	1
379	Tau liquid-liquid phase separation: At the crossroads of tau physiology and tauopathy. <i>Journal of Cellular Physiology</i> , 0, , .	2.0	4
380	The prion-like transmission of tau oligomers via exosomes. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	9
381	The gut-brain axis in the pathogenesis of Parkinson's disease. <i>Brain Science Advances</i> , 2019, 5, 73-81.	0.3	1
382	Connectome-based biophysics models of Alzheimer's disease diagnosis and prognosis. <i>Translational Research</i> , 2023, 254, 13-23.	2.2	1

#	ARTICLE	IF	CITATIONS
383	Populations of Tau Conformers Drive Prion-like Strain Effects in Alzheimer's Disease and Related Dementias. <i>Cells</i> , 2022, 11, 2997.	1.8	6
384	Towards a Mechanistic Model of Tau-Mediated Pathology in Tauopathies: What Can We Learn from Cell-Based In Vitro Assays?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11527.	1.8	4
385	Proteinopathies: Deciphering Physiology and Mechanisms to Develop Effective Therapies for Neurodegenerative Diseases. <i>Molecular Neurobiology</i> , 2022, 59, 7513-7540.	1.9	5
386	Single cell transcriptomic profiling of a neuron-astrocyte assembloid tauopathy model. <i>Nature Communications</i> , 2022, 13, .	5.8	14
387	Proline-Rich Region II (PRR2) Plays an Important Role in Tau's Glycan Interaction: An NMR Study. <i>Biomolecules</i> , 2022, 12, 1573.	1.8	1
388	Pathogenic Role of RAGE in Tau Transmission and Memory Deficits. <i>Biological Psychiatry</i> , 2023, 93, 829-841.	0.7	4
389	PICALM and Alzheimer's Disease: An Update and Perspectives. <i>Cells</i> , 2022, 11, 3994.	1.8	19
390	Common and Specific Marks of Different Tau Strains Following Intra-Hippocampal Injection of AD, PiD, and GGT Inoculum in hTau Transgenic Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15940.	1.8	4
391	The Impact of the Cellular Environment and Aging on Modeling Alzheimer's Disease in 3D Cell Culture Models. <i>Advanced Science</i> , 2023, 10, .	5.6	9
392	Human mini-brains for reconstituting central nervous system disorders. <i>Lab on A Chip</i> , 2023, 23, 964-981.	3.1	3
394	How Organ-on-a-Chip Technology Can Assist in Studying the Role of the Glymphatic System in Neurodegenerative Diseases. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2171.	1.8	5
395	Botulinum neurotoxin A modulates the axonal release of pathological tau in hippocampal neurons. <i>Toxicon</i> , 2023, 228, 107110.	0.8	2
396	The unique neuropathological vulnerability of the human brain to aging. <i>Ageing Research Reviews</i> , 2023, 87, 101916.	5.0	4
397	Toxic Tau Aggregation in AD. , 2023, , 1-30.		1
400	Mechanism of action deconvolution of the small-molecule pathological tau aggregation inhibitor Anle138b. <i>Alzheimer's Research and Therapy</i> , 2023, 15, .	3.0	0
403	Neuroanatomical Tract Tracers: Not Just for Neural Tracing Anymore. <i>ACS Applied Bio Materials</i> , 2023, 6, 1380-1397.	2.3	1
404	The Multifaceted Role of WNT Signaling in Alzheimer's Disease Onset and Age-Related Progression. <i>Cells</i> , 2023, 12, 1204.	1.8	1
417	Novel Therapeutic Targets for Treating Alzheimer's Disease. , 2023, , 19-39.		0

#	ARTICLE	IF	CITATIONS
421	Decoding the Cellular Trafficking of Prion-like Proteins in Neurodegenerative Diseases. Neuroscience Bulletin, 2024, 40, 241-254.	1.5	0
434	Î±-Linolenic Acid Induces Microglial Activation and Extracellular Tau Internalization. Methods in Molecular Biology, 2024, , 471-481.	0.4	0